title: Effect of magnesium pyridoxal 5-phosphate glutamate on the hamster cardiomyopathy.
abstract: 30-day-old polymyopathic hamsters (strain BIO 82.62) were orally treated with either magnesium pyridoxal 5-phosphate glutamate 100 mg/kg, equimolar amounts of magnesium alone (MgCl2 55 mg/kg), or water b.i.d. for 30 days, or sacrificed before treatment. 60-day-old healthy hamsters (strain CLAC) served as controls. Magnesium pyridoxal 5-phosphate glutamate lowered the myocardial calcium content (42.8 +/- 13.1 mmol/kg dry weight) as compared to MgCl2 (70.3 +/- 11.9 mmol/kg dry weight) and water (72.7 +/- 13.6 mmol/kg dry weight). The serum and tissue lipid pattern did not differ between BIO 82.62 and normal hamsters except high serum cholesterol and triglyceride levels in 30-day-old BIO 82.62 hamsters. Myocardial necroses were influenced by neither magnesium pyridoxal 5-phosphate glutamate nor MgCl2. Cytochemical investigation of the ultrastructural calcium localization in the aorta revealed less calcium precipitates with magenesium pyridoxal 5-phosphate glutamate in media myocytes. It is concluded that magnesium pyridoxal 5-phosphate glutamate exerts a calcium antagonistic effect in the cardiomyopathy of the Syrian hamster which is related neither to the magnesium content of magnesium pyridoxal 5-phosphate glutamate nor to its lipid lowering activity.
authors.affiliation: Abteilung für Kardiologie, Universität Frankfurt/Main, Fed. Rep. of Germany.
authors.forename: H G
authors.initials: HG
authors.lastname: Olbrich
authors.forename: J F
authors.initials: JF
authors.lastname: Boeker
authors.forename: S
authors.initials: S
authors.lastname: Rachor
authors.forename: U P
authors.initials: UP
authors.lastname: Ketelsen
authors.forename: H
authors.initials: H
authors.lastname: Wieland
authors.forename: G
authors.initials: G
authors.lastname: Kober
authors.forename: A
authors.initials: A
authors.lastname: Schmidt
authors.forename: E
authors.initials: E
authors.lastname: Mutschler
mesh_terms: D000818:Animals; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D009202:Cardiomyopathies / Q000188:drug therapy* / Q000473:pathology; D006224:Cricetinae; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood; D008274:Magnesium / Q000378:metabolism; D008647:Mesocricetus; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D009336:Necrosis / Q000188:drug therapy; D011732:Pyridoxal Phosphate / Q000627:therapeutic use*
chemical_list: D002121:Calcium Channel Blockers; D008055:Lipids; D011732:Pyridoxal Phosphate; D008274:Magnesium; D002118:Calcium